Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory ...
Taiwan News

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with ...

86% ORR, 63% CR rate, 53% PFS at 12 months in patients who received vispa-cel with an optimized profile (N=35) Vispa-cel is generally well-tolerated, allowing for administration in the outpatient ...

2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon

Pfizer › The healthcare industry revolves around constant innovation in areas like biotechnology, pharmaceuticals, medical ...
STAT

Caribou’s off-the-shelf CAR-T therapy shows promise in lymphoma study

Caribou Biosciences said its off-the-shelf CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.
The Bakersfield Californian

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell ...

Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at ...